Early Steroid Withdrawal After Kidney Transplantation in Patients at Risk for New-Onset Diabetes After Transplantation

被引:2
作者
Gierczak, Valentine [1 ]
Noble, Johan [1 ]
Malvezzi, Paolo [1 ]
Janbon, Benedicte [1 ]
Terrec, Florian [1 ]
Chevallier, Eloi [1 ]
Bennani, Hamza Naciri [1 ]
Bugnazet, Mathilde [1 ]
Imerzoukene, Farida [1 ]
Rostaing, Lionel [1 ,2 ]
Jouve, Thomas [1 ,2 ]
机构
[1] CHU Grenoble Alpes, Serv Nephrol Hemodialyse Aphereses & Transplantat, CS 10217, F-38043 Grenoble 09, France
[2] Univ Grenoble Alpes, Grenoble, France
关键词
RENAL-TRANSPLANTATION; LONG-TERM; CLINICAL-PRACTICE; FREE REGIMENS; FOLLOW-UP; HYPERGLYCEMIA; RECIPIENTS; MELLITUS; MULTICENTER; STRATEGIES;
D O I
10.1016/j.transproceed.2021.07.047
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. New-onset diabetes after transplantation (NODAT) is a serious complication after kidney transplantation because of worse graft survival and increased risk of cardiovascular events. It is partly induced by immunosuppressive therapies such as corticosteroids. This study aimed to assess whether early corticosteroid withdrawal on day 4 (early steroid withdrawal [ESW] group) could prevent the development of NODAT within 2 years posttransplantation while maintaining good graft and patient survival rates. Methods. This was an observational, single-center, retrospective study. All patients received an induction therapy of antithymocyte globulin or basiliximab and maintenance therapy of tacrolimus/mycophenolate mofetil/corticosteroids. Patients were either weaned off corticosteroids on day 4 (ESW group) or were maintained on corticosteroids for at least 3 months (standard group). NODAT was defined as the initiation of any oral hypoglycemic agent or insulin at 3 months and up to 2 years posttransplantation in previously nondiabetic recipients. Results. Between January, 1, 2010, and December 14, 2014, 492 recipients were included in this study; 88 received the ESW strategy, and 404 received the standard strategy. Age and body mass index (BMI) were significantly higher in the ESW group. The incidence of NODAT was 36.8% in the ESW group and 8.8% in the standard group (odds ratio [OR], 47.5; P < .001). Compared with a matched sample from the standard group that had the same probability to benefit from ESW at baseline, ESW was still associated with a significantly increased risk of NODAT (OR, 4.41; P = .018). Among recipients with a BMI >25 kg/m(2), the ESW strategy significantly decreased the risk of NODAT compared with the standard strategy (OR, 0.07; P = .013). Safety endpoints (eg, acute rejection, de novo-specific antibodies, graft function/survival) did not differ between groups. Conclusion. Despite a reassuring safety profile, ESW on day 4 after kidney transplantation only had a marginal effect on the incidence of NODAT.
引用
收藏
页码:2216 / 2226
页数:11
相关论文
共 27 条
[1]   Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2019 [J].
Cefalu, William T. ;
Berg, Erika Gebel ;
Saraco, Mindy ;
Petersen, Matthew P. ;
Uelmen, Sacha ;
Robinson, Shamera .
DIABETES CARE, 2019, 42 :S34-S45
[2]   Reduced exposure to calcineurin inhibitors in renal transplantation [J].
Ekberg, Henrik ;
Tedesco-Silva, Helio ;
Demirbas, Alper ;
Vitko, Stefan ;
Nashan, Bjorn ;
Guerkan, Alp ;
Margreiter, Raimund ;
Hugo, Christian ;
Grinyo, Josep M. ;
Frei, Ulrich ;
Vanrenterghem, Yves ;
Daloze, Pierre ;
Halloran, Philip F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (25) :2562-2575
[3]   Effect of a multifactorial intervention on mortality in type 2 diabetes [J].
Gaede, Peter ;
Lund-Andersen, Henrik ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591
[4]   The global role of kidney transplantation [J].
Garcia Garcia, Guillermo ;
Harden, Paul ;
Chapman, Jeremy .
LANCET, 2012, 379 (9820) :E36-E38
[5]   New-Onset Diabetes After Renal Transplantation Risk assessment and management [J].
Ghisdal, Lidia ;
Van Laecke, Steven ;
Abramowicz, Marc J. ;
Vanholder, Raymond ;
Abramowicz, Daniel .
DIABETES CARE, 2012, 35 (01) :181-188
[6]   New-onset diabetes after kidney transplantation: Incidence and associated factors [J].
Gomes, Vania ;
Ferreira, Florbela ;
Guerra, Jose ;
Bugalho, Maria Joao .
WORLD JOURNAL OF DIABETES, 2018, 9 (07) :132-137
[7]   The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD New features and the 'Ten Commandments' of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen [J].
Grant, Peter J. ;
Cosentino, Francesco .
EUROPEAN HEART JOURNAL, 2019, 40 (39) :3215-3217
[8]   Hyperglycemia in the Posttransplant Period: NODAT vs Posttransplant Diabetes Mellitus [J].
Gupta, Suruchi ;
Pollack, Teresa ;
Fulkerson, Candice ;
Schmidt, Kathleen ;
Oakes, Diana Johnson ;
Molitch, Mark E. ;
Wallia, Amisha .
JOURNAL OF THE ENDOCRINE SOCIETY, 2018, 2 (11) :1314-1319
[9]   10-year follow-up of intensive glucose control in type 2 diabetes [J].
Holman, Rury R. ;
Paul, Sanjoy K. ;
Bethel, M. Angelyn ;
Matthews, David R. ;
Neil, H. Andrew W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589
[10]   Prediabetes after kidney transplantation-a reason to worry? [J].
Jenssen, Trond G. .
KIDNEY INTERNATIONAL, 2019, 96 (06) :1280-1282